Verona Pharma plc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David S. Zaccardelli
- Full Time Employees
- 209
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3 More London Riverside London United Kingdom SE1 2RE
- IPO Date
- Apr 28, 2017
- CIK
- 0001657312
- Website
- veronapharma.com
- Similar Companies
- Business
- Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases, develops and commercializes innovative prescription medicines for chronic lung conditions including chronic obstructive pulmonary disease (COPD), non-cystic fibrosis bronchiectasis, cystic fibrosis and asthma; its lead product, Ohtuvayre (ensifentrine), is a first-in-class inhaled, selective dual inhibitor of phosphodiesterase 3 and 4 that provides bronchodilator and non-steroidal anti-inflammatory effects for COPD maintenance treatment in adults, approved by the US FDA in June 2024 following successful Phase 3 ENHANCE-1 and ENHANCE-2 trials. Founded in 2006 and headquartered in London, United Kingdom, with a wholly-owned US subsidiary in Raleigh, North Carolina, the company targets patients with significant unmet needs in respiratory care through nebulized formulations and is advancing a fixed-dose combination of ensifentrine with glycopyrrolate. In a major development, Merck & Co., Inc. (known as MSD outside the US and Canada) completed its acquisition of Verona Pharma on October 7, 2025, for approximately $10 billion at $107 per American Depositary Share, making it a wholly-owned subsidiary to bolster Merck's cardio-pulmonary portfolio while continuing Ohtuvayre commercialization and clinical programs in the US and pursuing regulatory approvals in the European Union and UK.
Oracle Corp Sees Significant Reduction in Jeremy Grantham's Portfolio
Mueller Industries Inc: A Key Focus in Mario Gabelli's Latest 13F Filing
Oracle Corp Sees Significant Reduction in Jeremy Grantham's Portfolio
Sumitomo Mitsui Trust Group Inc. Buys 205 Shares of Verona Pharma PLC American Depositary Share $VRNA
Verona Pharma PLC American Depositary Share (VRNA) Projected to Post Earnings on Monday
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
Shareholders of Verona Pharma Approve Proposed Acquisition by Merck
Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025
All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy
Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today
Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks
Weathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA Now
What Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)
VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
Major deals involving U.S. drugmakers and biotechs over the past decade
Merck to Buy Verona Pharma for Around $10 Billion
VRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verona Pharma plc Is Fair to Shareholders
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck